Scarica l'app Stockscreener
15.46
15.37%
2.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative? - simplywall.st
Sellas Life Sciences Rides a Sector Wave as Its Own Leukemia Trial Hits the Home Stretch - Ad-hoc-news.de
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
SELLAS Shares Climb 15% as Market Values Company $2.98 Billion Over Cash Pre-AML Update - TechStock²
Sebring Design Build Featured in Newsweek on Why Affluent Williamson County Homeowners Are Remodeling Instead of Moving - Yahoo Finance
Why SELLAS Life Sciences Group (SLS) Stock Is Up Today - Quiver Quantitative
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
3 Healthcare Funds to Play Safe as Fed Readies for Rate Hike - Yahoo Finance
SELLAS Soars as Leukemia Trial Readout Sparks Speculation - TipRanks
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales? - Yahoo Finance
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission - Yahoo Finance
Citadel Sold More Than $4 Billion of Situational Awareness Bets - Yahoo Finance
Is the Options Market Predicting a Spike in Latham Group Stock? - Yahoo Finance
IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
Goldman Says Slowing Inflation Is Best Path to Lower US Yields - Yahoo Finance
Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses? - Yahoo Finance
SELLAS Life Sciences Soars 7.9x in Three Years, But Valuation Screens as Stretched - finance.biggo.com
SELLAS Life Sciences Group (SLS) Shares Just Moved, So What Is Drawing Attention? - Yahoo Finance
SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress - Yahoo Finance
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SELLAS Life Sciences Group, Inc. (SLS) Latest Stock News & Headlines - Yahoo Finance
SELLAS Life Sciences Group (SLS) Nears Key Phase 3 Readout On A Pricey Valuation - simplywall.st
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
GOOGL Stock Drops In Premarket: Report Says Search Giant Trims Cloud Team Amid AI Spending Push - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS Stock Extends Rally To 4 Days: Jefferies Discloses New Stake, CEO Signals AML Database-Lock Preparations - Yahoo Finance
Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial - Stocktwits
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):